Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.55 |
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 0.55 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.55 |
| ▸ | PLAU | P00749 | 1/20 | 0.95 |
| ▸ | ANPEP | P15144 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8991950 | 1.00 | PLAU (0.95) | PLAUANPEPDRD2DRD3OPRK1 | |
| Hydrochloric Acid SCHEMBL4109114 | 1.00 | PLAU (0.95) | PLAUANPEPDRD2DRD3OPRK1 | |
| Hydrochloric Acid SCHEMBL29962303 | 1.00 | PLAU (0.95) | PLAUANPEPDRD2DRD3OPRK1 | |
| Hydrochloric Acid SCHEMBL5518794 | 1.00 | PLAU (0.95) | PLAUANPEPDRD2DRD3OPRK1 | |
| Hydrochloric Acid SCHEMBL8768594 | 1.00 | PLAU (0.95) | PLAUANPEPDRD2DRD3OPRK1 | |
| SCHEMBL895905 | 0.98 | PLAU (1.00) | PLAUANPEPDRD2DRD3OPRK1 | |
| SCHEMBL29428767 | 0.98 | PLAU (1.00) | PLAUANPEPDRD2DRD3OPRK1 | |
| SCHEMBL30368725 | 0.98 | PLAU (1.00) | PLAUANPEPDRD2DRD3OPRK1 | |
| SCHEMBL42952 | 0.98 | PLAU (1.00) | PLAUANPEPDRD2DRD3OPRK1 | |
| SCHEMBL30038968 | 0.98 | PLAU (1.00) | PLAUANPEPDRD2DRD3OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143322-A1 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE | PLT PATENT & LICENCE TRADING LTD., C/O THE B-NET (GB) | 2010-06-10 | — | — | US | claimed |
| EP-1917006-A2 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE | PLT Patent & Licence Trading Ltd. (GB) | 2008-05-07 | — | — | EP | claimed |
| WO-2006136454-A2 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE | PLT PATENT & LICENCE TRADING LTD. (GB) | 2006-12-28 | — | — | WO | claimed |
| EP-4685149-A1 | NOVEL COMPOUND AS ENDOTHELIAL TO MESENCHYMAL TRANSITION (ENDMT) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Korea Institute of Radiological & Medical Sciences (KR) | 2026-01-28 | — | — | EP | disclosed |
| EP-4351548-A2 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-113677334-B | Transient receptor potential MELASTATIN 8 (TRPM 8) antagonists and related methods | 马歇尔大学科研协会 | 2024-04-09 | — | — | CN | disclosed |
| WO-2023190878-A1 | TETRAHYDRONAPHTHALENE DERIVATIVE | Ａｔｒａｎｓｅｎ Ｐｈａｒｍａ株式会社 | 2023-10-05 | — | — | WO | disclosed |
| WO-2022261240-A2 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Life Sciences AG (DE) | 2022-12-15 | — | — | WO | disclosed |
| CN-113677334-A | Transient receptor potential MELASTATIN 8(TRPM8) antagonists and related methods | 马歇尔大学科研协会 | 2021-11-19 | — | — | CN | disclosed |
| US-9676756-B2 | Substituted pyrimidinyl kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| EP-3030560-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd (CH) | 2016-06-15 | — | — | EP | disclosed |
| WO-1998027050-A1 | PROCESS FOR PREPARING A NAPHTALENAMINE DERIVATIVE | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1998-06-25 | — | — | WO | disclosed |
| US-5719280-A | REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID | SYNTEX (U.S.A.) INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0757677-A1 | BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1997-02-12 | — | — | EP | disclosed |
| US-5538988-A | CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. | 1996-07-23 | — | — | US | disclosed |
| WO-1995029165-A2 | BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-11-02 | — | — | WO | disclosed |
| US-5272157-A | Derivatives of 4-(aminomethyl) piperidine, their preparation and their therapeutic application | SYNTHELABO (FR) | 1993-12-21 | — | — | US | disclosed |
| US-5179108-A | Antiserotonin agents or cardiovascular disorders | SYNTHELABO (FR) | 1993-01-12 | — | — | US | disclosed |
| EP-0415612-A2 | Use of sertraline for the treatment of chemical dependencies | PFIZER INC. (US) | 1991-03-06 | — | — | EP | disclosed |
| EP-0415613-A2 | Use of sertraline for the treatment of premature ejaculation | PFIZER INC. (US) | 1991-03-06 | — | — | EP | disclosed |